---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-057066"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T19:00:49.989404+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Celldex shareholders approve equity plan increase, elect directors including Denice Torres

## Summary
- Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.
- All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.
- Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.
- Advisory say-on-pay approved: 53.5M for, 627K against.
- Harry Penner elected Chair of board post-meeting.

## SEC filing metadata
- accession: 0001104659-25-057066
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/0001104659-25-057066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/tm2517205d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-057066
- JSON: https://secwatch.observer/filing/0001104659-25-057066.json
- Plain text: https://secwatch.observer/filing/0001104659-25-057066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.